Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q-period earnings results disclosed via press release exhibit: refer to Exhibit for actual financial figures.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q-period earnings results disclosed via press release exhibit: refer to Exhibit for actual financial figures
- Pipeline highlights flagged: ARCT-032 (respiratory) Phase 2 study sizing/timing, ARCT-810 (OTC disorder) regulatory alignment updates
- CSL Seqirus-partnered COVID-19 and flu programs cited as key external milestones to watch
- G&A expenses guided to "continue to decrease slightly": modest cost discipline signal
- Cash runway commentary included in press release: key liquidity metric for clinical-stage biotech investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.